Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond

Libby, Peter

doi:10.3390/cells10040951

Cited by 82 publications

(79 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is a major interaction between inflammation and thrombosis, all started from DAMPs, PRR activation and NLRP3 triggering. Inflammasomes act as amplification pathways not only for atherogenesis, but also for thrombosis [56].…”

Section: Atherosclerosis and Thrombosis: The Inflammatory Linkmentioning

confidence: 99%

Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging

Barbu

Popescu

et al. 2022

IJMS

View full text Add to dashboard Cite

Vascular disease was for a long time considered a disease of the old age, but it is becoming increasingly clear that a cumulus of factors can cause early vascular aging (EVA). Inflammation plays a key role in vascular stiffening and also in other pathologies that induce vascular damage. There is a known and confirmed connection between inflammation and atherosclerosis. However, it has taken a long time to prove the beneficial effects of anti-inflammatory drugs on cardiovascular events. Diabetes can be both a product of inflammation and a cofactor implicated in the progression of vascular disease. When diabetes and inflammation are accompanied by obesity, this ominous trifecta leads to an increased incidence of atherothrombotic events. Research into earlier stages of vascular disease, and documentation of vulnerability to premature vascular disease, might be the key to success in preventing clinical events. Modulation of inflammation, combined with strict control of classical cardiovascular risk factors, seems to be the winning recipe. Identification of population subsets with a successful vascular aging (supernormal vascular aging—SUPERNOVA) pattern could also bring forth novel therapeutic interventions.

show abstract

Section: Atherosclerosis and Thrombosis: The Inflammatory Linkmentioning

confidence: 99%

Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging

Barbu

Popescu

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…The authors concluded that activation of the NLRP3-inflammasome provides a general pattern in the inflammatory process of the underlying atherosclerosis, whereas the NLRP1-inflammasome seems to be specific for the pathogenesis of AOD [32]. The contribution of the NLRP3inflammasome to the process of atherosclerosis and its putative role as a therapeutic target is widely accepted [80][81][82]. While the NLRP3-inflammasome is attributed to metabolic dysfunction, the NLRP1-inflammasome is usually linked to autoimmunity [83].…”

Section: Inflammasomes In Aortic Atherosclerosis and Aortic Occlusive Disease (Aod)mentioning

confidence: 99%

Inflammasomes in the Pathophysiology of Aortic Disease

Wortmann

Peters

Erhart

et al. 2021

Cells

View full text Add to dashboard Cite

Aortic diseases comprise aneurysms, dissections, and several other pathologies. In general, aging is associated with a slow but progressive dilation of the aorta, along with increased stiffness and pulse pressure. The progression of aortic disease is characterized by subclinical development or acute presentation. Recent evidence suggests that inflammation participates causally in different clinical manifestations of aortic diseases. As of yet, diagnostic imaging and surveillance is mainly based on ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI). Little medical therapy is available so far to prevent or treat the majority of aortic diseases. Endovascular therapy by the introduction of covered stentgrafts provides the main treatment option, although open surgery and implantation of synthetic grafts remain necessary in many situations. Because of the risks associated with surgery, there is a need for identification of pharmaceutical targets interfering with the pathophysiology of aortic remodeling. The participation of innate immunity and inflammasome activation in different cell types is common in aortic diseases. This review will thus focus on inflammasome activities in vascular cells of different chronic and acute aortic diseases and discuss their role in development and progression. We will also identify research gaps and suggest promising therapeutic targets, which may be used for future medical interventions.

show abstract

“…CANTOS illustrated the central dilemma of many immunomodulatory strategies: Broad interventions in the immune system can have detrimental side effects. In general, anti-atherosclerotic strategies are geared toward suppression of vascular inflammation ( 5 , 8 , 15 ), whereas immune-based cancer treatments aim at enhancing immune responses against tumor cells ( 7 , 9 ). The therapeutic efficacy of several anti-cancer immunotherapies is constrained by their proimmunogenic (and thus proatherogenic) properties, increasing the risk to develop CVD in patients ( 16 ).…”

Section: Introductionmentioning

confidence: 99%

Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin

Nettersheim

Picard

Hoyer

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The development and clinical approval of immunotherapies has revolutionized cancer therapy. Although the role of adaptive immunity in atherogenesis is now well-established and several immunomodulatory strategies have proven beneficial in preclinical studies, anti-atherosclerotic immunotherapies available for clinical application are not available. Considering that adaptive immune responses are critically involved in both carcinogenesis and atherogenesis, immunotherapeutic approaches for the treatment of cancer and atherosclerosis may exert undesirable but also desirable side effects on the other condition, respectively. For example, the high antineoplastic efficacy of immune checkpoint inhibitors, which enhance effector immune responses against tumor cells by blocking co-inhibitory molecules, was recently shown to be constrained by substantial proatherogenic properties. In this review, we outline the specific role of immune responses in the development of cancer and atherosclerosis. Furthermore, we delineate how current cancer immunotherapies affect atherogenesis and discuss whether anti-atherosclerotic immunotherapies may similarly have an impact on carcinogenesis.

show abstract

Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond

Cited by 82 publications

References 128 publications

Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging

Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging

Inflammasomes in the Pathophysiology of Aortic Disease

Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin

Contact Info

Product

Resources

About